Collaboration and Decision-Support Tools to Mitigate Nirmatrelvir/Ritonavir Drug Interactions
Our management strategies efficiently and safely provided treatment to more than 60% of patients at high risk of disease progression who would otherwise have been excluded from receiving this medication option due to drug-to-drug interactions with nirmatrelvir/ritonavir.
Authors
- Cory Kudrna
- Yanjun Zhao (ORCID: https://orcid.org/0000-0003-1938-9848)
- Marsha L. Pike
- Sidna M. Tulledge‐Scheitel (ORCID: https://orcid.org/0000-0001-5634-8397)
- S Hirn
- Tammy L Schmit
- Nicole E Kriewall
Institutions
- Mayo Clinic in Arizona (US)
Publication Details
- Journal
- Clinical Nurse Specialist
- Published
- 2025-06-17
- DOI
- https://doi.org/10.1097/nur.0000000000000906
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00